Selank’s reputation as an anti-anxiety peptide rests on one controlled human trial, run by a single Russian research group, and that trial measured Selank against an existing anxiolytic drug rather than against a placebo. That distinction gets lost in most write-ups of this compound, and it matters: the data show Selank can perform about as well as an older tranquilizer in a clinical population. They do not show it beats doing nothing, because nobody ran that comparison.
What the strongest human evidence for Selank shows
Sixty-two patients with generalized anxiety disorder or neurasthenia entered the trial that anchors nearly every benefits claim made about this peptide. Thirty received Selank, thirty-two received the anxiolytic medazepam, and the anxiolytic effects in the two groups came out similar[1].
62 total patients in Selank's only published anxiolytic RCT PMID 18454096
Selank did do one thing medazepam didn’t. Patients on it also showed antiasthenic and psychostimulant effects, on top of the anxiolytic response[1]. That’s a real finding, and it’s also the entire finding: one trial, one comparator, one research group.
Selank itself is described as a synthetic analog of tuftsin, an immune-signaling peptide. That lineage comes from a 2014 study that gave Selank and its short fragment Gly-Pro to mice and tracked immune-gene expression in spleen tissue, not from any analysis of human tissue[2].
No placebo-controlled trial of Selank for anxiety has been published. Every claim about its anxiolytic benefit traces back to a design that can only ask “does it match an existing drug,” never “does it beat nothing at all.”
What an active-comparator trial can and cannot prove
A trial without a placebo arm still tells you something. It just doesn’t tell you what most marketing implies it tells you. Here’s the actual scope of what the medazepam comparison supports:
What it can show: that Selank and medazepam produced similar changes on the same rating scales, in the same population, over the same treatment window.
What it can’t show: that either drug outperformed no treatment. Anxiety symptoms fluctuate and respond to attention and expectation on their own, and a two-arm active-comparator design has no way to separate that from a genuine drug effect.
What it does establish: a randomized, interventional comparison, which is a meaningfully stronger design than an observational study of people who chose to take Selank on their own. Within the trial, the similarity between arms is a genuine causal result rather than a mere correlation.
That’s a narrower claim than “Selank works for anxiety.” It’s closer to “Selank performed like a benzodiazepine-adjacent drug in one small trial that wasn’t built to test against nothing.”
One proposed mechanism has more direct human support than the rest of Selank’s pharmacology. In patients with anxiety and phobic disorders, Selank dose-dependently inhibited the enzymatic breakdown of plasma enkephalin, with an IC50 around 15 micromolar, and it did so more potently than the peptidase inhibitors bacitracin and puromycin[3]. That’s a proposed biochemical basis for an anxiolytic effect that runs through the opioid-adjacent enkephalin system, distinct from how benzodiazepines act on GABA receptors.
Mechanism: what has human data, what is still animal work
The enkephalinase finding above is worth separating out because it was measured directly in blood and plasma from patients with anxiety and phobic disorders, not extrapolated from a rodent model[3]. That gives it more direct human grounding than most of what else gets cited for Selank.
Most of Selank's mechanistic evidence sits on the mouse side of that line.
Everything else sits on the mouse side of that line. In BALB/c and C57BL/6 mice, a 0.3 mg/kg dose of Selank raised norepinephrine in the hypothalamus of both strains, but it pushed dopamine metabolites (DOPAC, HVA) in opposite directions depending on strain, and it lowered serotonin and its metabolite only in the BALB/c animals[4]. If a single peptide produces opposite neurochemical shifts depending on which inbred mouse line receives it, that is not a mechanism ready to generalize to a genetically diverse human population.
Selank also alters gene expression tied to immune function. In mice, Selank and its short fragment Gly-Pro produced a significant threefold drop in complement C3 mRNA within 30 minutes of injection, along with shifts in several other immune-related genes in spleen tissue[2]. It’s a genuinely interesting finding about Selank’s origin as a tuftsin analog. Nothing published connects it to the peptide’s behavioral or anxiolytic effects in humans.
The mechanism gap: Selank has one mechanism with direct human plasma data (enkephalinase inhibition) and several with only mouse data. Marketing copy rarely draws that line. The trials do.
What the evidence does not establish
No published randomized trial has tested Selank for cognitive enhancement or nootropic effects in healthy adults. The one human trial that exists enrolled patients with diagnosed generalized anxiety disorder or neurasthenia, a clinical population chasing symptom relief rather than healthy volunteers chasing sharper focus.
That gap doesn’t stop the claims from circulating anyway:
The memory and focus claims extrapolate from a clinical anxiolytic trial in a sick population and from rodent neurochemistry data, neither of which measured cognitive performance in a healthy human brain.
The “smart drug” framing treats strain-dependent mouse neurochemistry as if it predicted a uniform human cognitive effect, when the mouse data itself shows the opposite: the response depends heavily on genetic background.
Nobody has run the trial that would support the nootropic claim. Until someone does, it’s a marketing inference sitting on top of an anxiety study.
Where Selank fits against benzodiazepines and Semax
Selank’s best safety-adjacent finding shows up when you add it to a benzodiazepine rather than use it alone. In a trial comparing phenazepam alone (30 patients) to phenazepam plus Selank (40 patients) in patients with anxiety-phobic, hypochondriac, or somatoform disorders, adding Selank reduced the side effects associated with phenazepam, including attention and memory impairment, asthenia, sedation, longer sleep duration, sexual disturbances, emotional indifference, and orthostatic symptoms, both during treatment and after the benzodiazepine was withdrawn[5]. For more on what Selank’s own side-effect profile does and doesn’t cover, see Selank’s side effects are barely documented in humans.
Selank is frequently discussed alongside Semax, a related peptide from the same Russian research program. The two have been directly compared for pharmacological effects such as anticoagulant activity, in a 2006 study of glyproline-class peptides[6], but not in a head-to-head clinical efficacy trial for anxiety. Anyone choosing between them on the basis of comparative human data is choosing on vibes rather than evidence. See Semax vs Selank: two Russian peptides, one shared evidence problem for the fuller comparison.
Benzodiazepines are the honest yardstick here, and Selank doesn’t clear it. Benzodiazepines carry decades of placebo-controlled trial data, run across many independent research groups and populations. Selank has one small trial from one institute, and its finding, that it performs similarly to an older anxiolytic, is real but thin next to that comparison.
Selank's published human evidence
Study | Design | Patients | Finding |
|---|---|---|---|
Zozulia et al, 2008 | Randomized, active comparator (no placebo) | 62 (GAD or neurasthenia) | Selank matched medazepam's anxiolytic effect, plus antiasthenic and psychostimulant effects |
Medvedev et al, 2015 | Randomized, add-on comparison | 70 (anxiety-phobic, hypochondriac, or somatoform disorders) | Adding Selank to phenazepam reduced the benzodiazepine's side effects |
Zozulya et al, 2001 | Mechanistic, human plasma | Patients with anxiety and phobic disorders | Selank dose-dependently inhibited enkephalin-degrading enzymes (IC50 about 15 uM) |
The three studies that carry Selank's benefits and mechanism claims in humans.
What would have to happen for this picture to change
Nearly all published human data on Selank comes from a single Russian research institute. No independent replication of its anxiolytic trial has appeared in an international journal outside that group’s own output.
Two specific gaps stand between “suggestive” and “established” here:
A placebo-controlled trial. Without one, there’s no way to separate Selank’s effect from the natural fluctuation of anxiety symptoms and the effect of simply being enrolled in a study.
Independent replication. A finding that comes from one lab, using one set of rating scales, on one patient population, remains a starting point rather than a settled result.
For readers who want the dosing and duration used in the existing trial rather than the marketing version of it, Selank for Anxiety: What the Research Protocols Show lays out what was administered.
Until a placebo arm and a second research group show up in the literature, the honest description of Selank’s benefit is narrow: it matched an old anxiolytic in one small trial, and reduced that drug’s side effects when added to it in another. That’s a real, specific result. It’s also the ceiling of what’s been shown, not a floor for what marketing keeps building on top of it.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008.
The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action.. Molecular immunology, 2014.
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.. Bulletin of experimental biology and medicine, 2001.
[Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study].. Eksperimental'naia i klinicheskaia farmakologiia, 2008.
[Optimization of the treatment of anxiety disorders with selank].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015.
[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].. Izvestiia Akademii nauk. Seriia biologicheskaia, 2006.
